Advisory boutique · United States

Gordon Dyal & Co.

Deals
2
Latest
Jan 2026
Compare

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deal size
Custom range

2 of 2 deals

Deals Gordon Dyal & Co. advised on, most recent first
Advisers
Jan 2026 Mersana Therapeutics –Day One BiopharmaceuticalsAcquisitionFinancial adviser to Day One (acquirer)Completed–Biotech+2 Fenwick & West (buy-side)TD Securities (sell-side)WilmerHale (sell-side) Day One Biopharmaceuticals acquisition of Mersana Therapeutics
Oct 2025 Avidity Biosciences –NovartisAcquisitionFinancial adviser to Novartis AG (acquirer)Announced11,000.0Biotech+2 Goldman Sachs (sell-side)Barclays (sell-side)Kirkland & Ellis (sell-side)Covington & Burling (buy-side)Freshfields (buy-side) Novartis acquisition of Avidity Biosciences
Suggest a correction

A missing deal, a wrong role or an office to add. A link to a public source helps.